Delivered 160 basis points of operating margin expansion by intentionally shifting the customer mix toward more profitable managed care, progressive lens, and 'Outside Rx' segments.

Modernized the frame assortment by increasing the mix of products priced above $99 from 20% to 40% during the year, directly addressing previous underdevelopment in premium categories.

Transitioned marketing from a purely promotional 'two-pair' offer to a brand-led strategy, successfully reaching higher-income demographics while maintaining a value-oriented core.

Implemented a consultative selling model supported by digital tools like iPads and OptiCam, moving store associates away from transactional interactions to drive higher average tickets.

Achieved record doctor retention and recruiting by offering flexible practice models, including a remote-hybrid system where in-store doctors perform exams for other locations.

Leveraged a 6% adjusted comp store sales growth to drive SG&A efficiency, complemented by a disciplined culture of cost management across all enterprise levels.

Guidance for 3% to 6% comp store sales assumes a continued shift in customer mix, with ticket growth offsetting potential short-term traffic declines in the self-pay cohort.

Expects to scale Ray-Ban Meta smart glasses to the entire store fleet by the end of Q2 2026 following high sell-through and premium lens attachment rates in initial tests.

Plans to further evolve the frame board to approximately 70% branded frames by year-end 2026, up from 40% today, through a new five-tier store merchandising segmentation.

Anticipates closing the 'lens gap' versus the category by introducing a tier-four progressive lens and migrating premium materials to approach 60% of the total mix.

Assumes approximately $10,000,000 in annualized cost savings as part of a multiyear efficiency plan focused on logistics, procurement, and support center optimization.

The 53rd week in fiscal 2025 contributed $35,600,000 in net revenue and $3,500,000 in adjusted operating income, creating a high bar for year-over-year comparisons in 2026.

Winter storms in early 2026 impacted approximately 15% of the store fleet, though management noted sequential traffic acceleration from the fourth quarter despite these weather headwinds.

Entered into a $100,000,000 interest rate hedge at a fixed rate of 3.43% to mitigate exposure to short-term rate volatility on outstanding debt.

Authorized a new $50,000,000 share repurchase program through 2030, signaling confidence in cash flow despite a primary focus on organic growth investments.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management expects the cash-pay cohort to comp positively in 2025 as these customers opt into premium products faster than originally anticipated.

The strategy involves a multiyear, intentional walk away from some price-sensitive promotional traffic to reinvest in higher-value acquisition channels.

Meta AI glasses are driving some of the highest-value transactions in the store due to a 'vast majority' attachment rate of prescription and premium lenses.

While not yet a material percentage of total revenue, the product serves as a critical proof point for the brand's ability to attract tech-forward, higher-spending customers.

Managed care currently sits at 42% of revenue, and management reaffirmed 50% as the 'North Star' goal.

Reaching this target requires disproportionate growth in insurance-backed customers, which is being supported by the new media partner and mid-funnel digital advertising.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.